4.1%) and others (n=4, 2.0%). The prevalence of work disability was 35% (n=69) and the onset of WD was 4 (IQR:1 to 9) years after SLE diagnosis. WD was associated with older age, lower education level, more frequent disease flare, longer disease duration, higher SLICC ACR Damage Index, active disease (SLEDAI 2K and BILAG 2004 and had major organ involvement (lupus nephritis, haematological and neuropsychiatric), all $p<0.05$. Patients who received plasmapheresis, intravenous methylprednisolone, intravenous immunoglobulin, Mycophenolate Mofetil and calcineurin inhibitors were also associated with WD. Patients with work disability also had significantly impaired QOL with lower SF 36 scores. On multivariate logistic regression analysis, the independent predictors of WD were lower education level, being married and involvement of lupus nephritis, haematological and neuropsychiatric lupus (NPSLE).

Conclusions: More than one third of SLE patients had experienced work disability. Lower education level, being married and major organ involvement were the independent predictors for work disability. A larger prospective study is warranted to further delineate the risk factors.

REFERENCES:

- [1] Garris C, et al. Impact of systemic lupus erythematosus on burden of illness and work productivity in the United States. *Lupus* 2013;22:1077–1086.
- [2] Mok CC, et al. Risk and predictors of work disability in Chinese patients with SLE. *Lupus* 2008;17:1103–1107.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1185

FRI0387 FACTORS ASSOCIATED WITH OSTEOPOROSIS AND FRACTURE IN PATIENTS WITH SJÖGREN PRIMARY SYNDROME

T. Salman Monte¹, V. Torrente-Segarra², C. Sanchez-Piedra³, M. Fernández Castro⁴, J.L. Andreu⁵, A. Olivé⁶, J. Rosas⁷, V. Martínez Taboada⁸ on behalf of SJOGRENSER project (GEEAS-SER). ¹Rheumatology, Parc de Salut Mar/IMM. Barcelona; ²Rheumatology, H.de L'Hospitalet, Barcelona; ³Unidad de Investigación de la SER. Madrid; ⁴Rheumatology, H. Infanta Sofía. Madrid; ⁵Rheumatology, H. Puerta de Hierro, Madrid; ⁶Rheumatology, H. Germans Trias i Pujol, Barcelona; ⁷Rheumatology, H. Marina Baixa, Alicante; ⁸Rheumatology, H. Marqués de Valdecilla, Santander, Spain

Background: Primary Sjögren's syndrome (SSp) is a systemic autoimmune disease characterised by exocrine gland affection and multisystem involvement. In addition to the systemic inflammatory affection, patients with pSS have additional risk factors to develop osteoporosis (OP) and its major complication, osteoporotic fracture.

Objectives: The aim of the study is to determine the sociodemographic and clinical factors of pSS associated with the presence of OP and osteoporotic fracture in patients with pSS from the SJOGRENSER registry.

Methods: SJOGRENSER is a descriptive, cross-sectional and multicenter study of patients with pSS classified according to European-American consensus criteria. Patients attended in consultations of 33 Spanish rheumatology services were randomly included. Both the medical history and the medical interview were used to obtain the data. Epidemiological, clinical, serological and complications were collected. The continuous and categorical variables were analysed by means, medians and frequencies, with their respective deviations and interquartile ranges (p25-p75). Bivariate and multivariate analyses were carried out using a binomial logistic regression to study the factors associated with osteoporosis and osteoporotic fracture in pSS.

Results: In the SJOGRENSER registry, 437 patients were included (95% women, with a median age of 58.63 (50.02–67.98) years). The prevalence of OP in the cohort was 18.54% (81 patients). The prevalence of OP in men (n=21) was 19%, 2 men in the age group of 51–64 years and 2 in the group of >64 years. Three hundred of the women in the registry were menopausal (76.4%); a total of 67/300 women with menopause had OP (15%). A total of 37 osteoporotic fractures (8.5%) were recorded in the cohort. Factors associated with OP in women with SSp in the bivariate analysis were: age (60.5% in the group of >64 years, 28% in the group of 51–64 years and 2.6% in the group ≤50 years, $p<0.001$), the time course of the disease (11.35 (SD 7.95) vs 7.8 (SD 6.14), $p<0.001$), the age of menopause (47 (SD 7.29) vs 48.11 (SD 5.67), $p=0.020$), the ESSDAI (6 (DS 7) vs 4 (DS 5), $p=0.020$), and presence of anti-La (77.6% vs 64.7%, $p=0.030$). In the multivariate analysis, there was an association between OP and age in the 51–64 age group, OR 9.993 (95% CI, 2.301–43.399, $p=0.002$), age >64 years, OR 20.610 (CI 95% 4.679–90.774, $p<0.001$) and time course of the disease, OR 1.046 (95% CI 1.008–1.085, $p=0.017$). Similarly, an association was found between the fracture and age in the 51–64 age group, OR 5.068 (95% CI, 1.117–22.995, $p=0.035$), age >64 years, OR 7.674 (95% CI 1.675–35.151, $p<0.009$), the time course of the

disease, OR 1.049 (95% CI 1.003–1.097, $p<0.036$) and the ESSDAI score, OR 1.080 (95% CI, 1.029–1.134, $p=0.002$).

Conclusions: Patients with pSS have a considerable prevalence of osteoporosis and osteoporotic fracture. Age and time of evolution were factors associated with the development of OP, and similarly, age, time of evolution of the disease and ESSDAI were factors associated with the development of fracture in patients with pSS.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3985

FRI0388 RISK OF PREVENTABLE ADMISSIONS AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS PRIOR AND SUBSEQUENT DIAGNOSIS

T.-T. Chung¹, C.-F. Kuo^{1,2}, J.-S. Chen¹, M.-J. Chiou¹. ¹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China; ²Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Nottingham, UK

Background: Preventable hospitalizations for specific conditions are considered preventable because appropriate outpatient care should potentially avoid hospitalisation for these conditions. Although not all of the hospitalizations can be prevented, to identify the rate of preventable hospitalizations among patients with systemic lupus erythematosus (SLE) can help us to understand the excess potential preventable hospitalizations and to provide an action to the SLE patients.

Objectives: To investigate the risk of preventable hospitalisation in patients with SLE before and after initial diagnosis of the disease.

Methods: We identified 4483 adult patients with incident SLE between 2005 and 2009 using the Taiwan National Health Insurance Database. Each SLE patients were matched to five controls without SLE during the same study period, by age and sex. The index date was the first date of SLE diagnosis and their matched controls. We estimated the incidence and incidence rate ratios (IRRs) of preventable hospitalisation by conditional Poisson regression, adjusted for age, sex, Elixhauser Comorbidity Index, number of outpatient visits and hospitalizations 1-y prior to index date, residence urbanisation, income levels, occupation and the number of physicians at the patients' residence.

Results: The overall incidence of preventable hospitalisation was 1.88 (95% CI, 1.74 to 2.03) per 1000 person-months among SLE patients and 0.53 (95% CI, 0.49 to 0.56) per 1000 person-months among controls, giving an adjusted IRR of 3.57 (95% CI, 3.25 to 3.93). The IRRs especially higher in heart failure, bacterial pneumonia and urinary tract infection and the respective estimates were 2.85 (95% CI, 2.14 to 3.80), 4.67 (95% CI, 4.03 to 5.42) and 3.84 (95% CI, 3.35 to 4.41).

Conclusions: Risk of preventable hospitalisation is higher in patients with SLE.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6959

FRI0389 BIOMARKERS AS DISEASE ACTIVITY INDICANTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

V. Zivkovic¹, T. Cvetkovic², B. Mitic³, B. Stamenkovic¹, S. Stojanovic¹, M. Stojanovic⁴, B. Radovanovic Dinic⁵. ¹Institute for Treatment and Rehabilitation "Niska Banja"; ²Clinic of Nephrology, Clinical centre; ³Clinic of Nephrology, Clinical Centre; ⁴Faculty of Medicine University of Nis; ⁵Clinic of Gastroenterology and Hepatology, Clinical Centre, Nis, Serbia

Background: In recent years, the search has been going on for the biomarkers potentially useful in the follow-up of patients with systemic lupus erythematosus (SLE).

Objectives: The aim of our study was to establish the importance of various immunological and biological parameters as disease activity indicants in SLE.

Methods: The study involved 85 SLE patients in whom disease activity assessment was performed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). In addition to standard anti-dsDNA antibodies and C3 complement component, anti-nucleosome and anti-C1q antibodies and monocyte chemoattractant protein-1 (MCP-1) were determined in the serum and urine. The antibodies were determined using the ELISA test, while serum and urine MCP1 was determined using the sandwich enzyme immunosorbent assay in accordance with the instructions by the manufacturer, R and D Systems, Inc. Minneapolis (USA).

Results: The studied group consisted of 78 women and 7 men, with the mean age of 45.27±9.71 years and average disease duration of 10.37±7.99 years. Univariate linear regression analysis showed that all of the examined parameters with the exception of C3 complement demonstrated a statistically significant impact on the SLEDAI values (for anti-dsDNA $p=0.033$, anti-nucleosome $p=0.002$, anti-C1q antibodies $p=0.005$, serum MCP1 $p=0.006$, urinary MCP1